Research Topics
Species | Takayasu KurataSummaryAffiliation: Kinki University Country: Japan Publications
| Collaborators
|
Detail Information
Publications
Efficacy and safety of denosumab for the treatment of bone metastases in patients with advanced cancerTakayasu Kurata
Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
Jpn J Clin Oncol 42:663-9. 2012..In this article, the efficacy and safety of denosumab for the treatment of bone metastases in patients with various advanced cancers are discussed...- A phase I/II study of carboplatin plus gemcitabine for elderly patients with advanced non-small cell lung cancer: West Japan Thoracic Oncology Group Trial (WJTOG) 2905Takayasu Kurata
Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
Lung Cancer 77:110-5. 2012..However, it is unclear whether elderly patients with a good performance status can tolerate platinum-doublet chemotherapy like younger patients... - A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904)Takayasu Kurata
Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka 589 8511, Japan
Jpn J Clin Oncol 40:992-4. 2010..We could not determine the recommended dose of this combination because of intolerable toxicities and no efficacy. Therefore, it is difficult to forward this combination chemotherapy toward further studies... - A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trialTakayasu Kurata
Department of Medical Oncology, Kinki University, School of Medicine, Osaka Sayama, Osaka, Japan
J Thorac Oncol 4:644-8. 2009..A phase I study on relapsed small cell lung cancer (SCLC) was conducted to establish the toxicity and maximum tolerated dose of carboplatin with topotecan, and to observe the antitumor activity... - Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group studyIsamu Okamoto
Kinki University Faculty of Medicine, Osaka City General Hospital, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
J Clin Oncol 28:5240-6. 2010.... - Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumorsKazuhiko Nakagawa
Kinki University School of Medicine, 377 2 Ohnohigashi, Osakasayama, Osaka 589 0014, Japan
Jpn J Clin Oncol 39:116-23. 2009.... 
Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancerTomohiro Ozaki
Department of Medical Oncology, Kinki University School of Medicine, Nara Hospital, Otoda, Ikoma, Nara, Japan
Anticancer Res 27:2657-65. 2007..The primary objective of this study was to determine the maximum tolerated dose (MTD), the toxicity profile and the recommended dose (RD) for phase II of a combination of S-1 and weekly administration of docetaxel...- A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patientsHiroyasu Kaneda
Department of Medical Oncology, Kinki University School of Medicine, Osaka 589-8511, Japan
Anticancer Res 26:2479-85. 2006..CONCLUSION: These data suggest that the combination of CPT-11 and AMR is not tolerated, as it mediates an unexpectedly strong myelosuppressive effect, and is inactive against both NSCLC and SCLC... - Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinibKazuyuki Tsujino
Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka, Japan
J Thorac Oncol 4:994-1001. 2009..However, a relationship between clinical response and survival benefit has not been well studied in the patients treated with molecular targeted agents... - Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failureKoichi Azuma
Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohnohigashi, Osakasayama, Osaka 589 8511, Japan
Biochem Biophys Res Commun 407:219-24. 2011.... - Skeletal metastases in non-small cell lung cancer: a retrospective studyAsuka Tsuya
Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama City, Osaka 589 8511, Japan
Lung Cancer 57:229-32. 2007..Therefore, we planned a retrospective study to investigate the clinical impact of SREs, and to compare differences in the therapeutic outcome between patients with and without skeletal metastases or SRE... - Amrubicin for non-small-cell lung cancer and small-cell lung cancerTakayasu Kurata
Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
Invest New Drugs 25:499-504. 2007..6 and 10.3 months, and 1-year survival rate was 46 and 40%, respectively. These results are promising for the treatment of both NSCLC and SCLC. Further clinical trials will clarify the status of amrubicin in the treatment of lung cancer... - Amrubicin for the treatment of advanced lung cancerTakayasu Kurata
Osaka Medical College, Division of Cancer Chemotherapy Center, Takatsuki, Osaka, Japan
Expert Opin Drug Metab Toxicol 5:171-80. 2009..The preclinical, pharmacology and clinical data of amrubicin for the treatment of advanced lung cancer are reviewed... - Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week coursesKenji Tamura
Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
Cancer Chemother Pharmacol 60:285-93. 2007.... - Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumorHidetoshi Hayashi
Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka Sayama, Osaka, Japan
Cancer Sci 104:98-104. 2013..In conclusion, OTS11101 was well tolerated in patients up to 3.0 mg once weekly and our biomarker analysis suggested that this anti-angiogenesis vaccine is biologically active... - [Evidence-based practice guideline for unresectable advanced lung cancer in 2003]Masahiro Fukuoka
Department of Medical Oncology, Kinki University School of Medicine
Nippon Geka Gakkai Zasshi 105:412-6. 2004..Recent randomized controlled trial demonstrated that irinotecan and cisplatin is superior to etoposide and cisplatin, a standard treatment of extensive-disease SCLC. This practice guideline should be updated periodically... - Pemetrexed-induced edema of the eyelidTakayasu Kurata
Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi Osaka Sayama, Osaka 589 8511, Japan
Lung Cancer 54:241-2. 2006..We experienced a patient who developed the valuable edema of the eyelid. We believe that medical oncologists should be aware of this rare adverse event, although the mechanism responsible for it is not yet known... - Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancerHiroyasu Kaneda
Department of Medical Oncology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan
Lung Cancer 46:247-54. 2004..CONCLUSIONS: Gefitinib provided clinical benefit for the following factors 'female', 'good PS' and 'non-smoker'. A low smoking index is reported as a novel predictive prognostic factor following a single regimen of gefitinib... - Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycinKimio Yonesaka
Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
Int J Cancer 118:812-20. 2006..siRNA targeting of survivin could be potentially useful for increasing sensitivity to anticancer drugs, especially in drug-resistant cells with mutated p53... - Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer?Takayasu Kurata
Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
J Thorac Oncol 1:684-91. 2006.... - First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumoursYasuhito Fujisaka
Osaka Medical College, Osaka, Japan
Invest New Drugs 31:108-14. 2013..Saracatinib (AZD0530) is a selective, oral Src inhibitor that has demonstrated antitumour activity in preclinical studies... 
Gemcitabine: efficacy in the treatment of advanced stage nonsquamous non-small cell lung cancerHidetoshi Hayashi
Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Japan
Clin Med Insights Oncol 5:177-84. 2011..This is a review of the past trials and reviews of first-line treatment for advanced NSCLC, focusing on efficacy and safety of treatment with gemcitabine according to histological subtype...